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Abstract
Background: Despite great progress made in methods to prevent mother-to-child transmission of HIV (MTCT),
delivery and uptake of these measures remains a challenge in many countries. Although the Brazilian Ministry of
Health aimed to eliminate MTCT by 2015, infection still occured in 15–24% of infants born to HIV-infected mothers.
We sought to identify remaining factors that constrain MTCT elimination.
Methods: We conducted a retrospective, matched case-control study by reviewing hospital charts of infants born
to HIV-infected mothers between 1997 and 2014 at three MTCT reference hospitals in the Rio de Janeiro
metropolitan area. Cases were defined as HIV-exposed children with two positive HIV tests before 18 months of
age; controls were defined as HIV-exposed children with two negative HIV tests before 18 months of age. We
performed bivariate and MTCT cascade analyses to identify risk factors for MTCT and gaps in prevention services.
Results: We included 435 infants and their mothers (145 cases, 290 controls). Bivariate analyses of MTCT preventative
care (PMTCT) indicated that cases were less likely to complete all individual measures in the antenatal, delivery, and
postnatal period (p < 0.05). Assessing completion of the PMTCT cascade, the sequential steps of PMTCT interventions,
we found inadequate retention in care among both cases and controls, and cases were significantly less likely than
controls to continue receiving care throughout the cascade (p < 0.05). Motives for incompletion of PMTCT measures
included infrastructural issues, such as HIV test results not being returned, but were most often due to lack of
care-seeking. Over the course of the study period, PMTCT completion improved, although it remained below the 95%
target for antenatal care, HIV testing, and antenatal ART set by the WHO. Adding concern, evaluation of co-infections
indicated that case infants were also more likely to have congenital syphilis (OR: 4.29; 95% CI: 1.66 to 11.11).
Conclusions: While PMTCT coverage has improved over the years, completion of services remains insufficient. Along
with interventions to promote care-seeking behaviour, increased infrastructural support for PMTCT services is needed
to meet the HIV MTCT elimination goal in Brazil as well as address rising national rates of congenital syphilis.
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Background
Without prophylactic treatment, mother-to-child trans-
mission (MTCT) occurs in approximately 20–45% of in-
fants born to HIV-infected women [1]. However, with
current measures to prevent MTCT (PMTCT), the fre-
quency can be reduced to < 2% in non-breastfeeding pop-
ulations [2]. Despite having an internationally recognized
approach to the prevention and treatment of HIV, Brazil
has not yet reached its goal of elimination of MTCT [3].
In 2011, the Brazilian Ministry of Health (BMoH)
launched the “Stork Network” (“Rede Cegonha”) [4] in
support of the UNAIDS goal to eliminate MTCT by 2015
[5], strengthening efforts toward early testing and anti-
retroviral (ARV) administration within the public health
system. However, by 2015, the frequency of MTCT in
Brazil was estimated to still be between 15 and 24% [6].
Per Brazilian national guidelines, the series of inter-
ventions used to identify and treat HIV-infected preg-
nant women and their infants, known as the PMTCT
cascade [7], begin with antenatal care, where a pregnant
woman is tested for HIV and administered antiretroviral
therapy (ART) if found to be infected. Starting in 1996,
antenatal HIV-infected women were offered zidovudine
(AZT); in 2007, all HIV-infected women with CD4 cell
count of < 200 cells/mL and/or plasma viral load of > 1000
copies/mL were offered triple ARV prophylaxis; since
2010, all HIV-infected women have been offered triple
ARV prophylaxis in the antenatal period [8]. During deliv-
ery, HIV-infected pregnant women receive intravenous in-
fusion of AZT, and infants are delivered by Caesarean
section if maternal viral load is > 1000 copies/mL or un-
known. Finally, during the postnatal period, HIV-exposed
infants are treated with oral ARVs and fed a formula-only
diet when possible. Supporting the PMTCT cascade,
Brazil has offered free ART nationwide since 1996 [9],
and has provided free formula for HIV-exposed infants
since 2002 [8].
Because of the failure of current prevention efforts to
reduce MTCT to targeted levels, in 2014 the BMoH
called for increased research into vertical transmission
to identify treatment gaps and underserved populations
[10]. In the present study, we conducted a retrospective
analysis to evaluate completion of the PMTCT cascade
and determine risk factors for MTCT at three PMTCT
reference hospitals in Greater Rio de Janeiro, the second
most populous metropolitan area in Brazil.
Methods
Study setting and population
This retrospective case-control study was carried out at
three PMTCT reference hospitals in the Rio de Janeiro
metropolitan area. The Instituto Nacional de Saúde da
Mulher, da Criança e do Adolescente Fernandes Figueira
(IFF), located in the south zone of Rio de Janeiro, and
the Hospital Federal dos Servidores do Estado (HFSE),
located in the city centre, are tertiary hospitals that serve
as the PMTCT reference centres for 58% of primary care
units in Rio de Janeiro [11]. The Hospital Geral de Nova
Iguaçu (HGNI) is located in a region of suburbs north of
Rio de Janeiro called the Baixada Fluminense, and an
estimated 12% of HIV-infected women in the state of
Rio de Janeiro receive care at this hospital [12].
We reviewed hospital records to identify infants born
to HIV-infected mothers between 1997, when ARVs be-
came universally available in Brazil for PMTCT, and
2014. Cases were defined as HIV-exposed children with
two detectable HIV viral load tests; controls were de-
fined as HIV-exposed children with two undetectable
HIV viral load tests, at least one of which done after
4 months of age. For each included case, two time- and
study site-matched controls—the last HIV-exposed, un-
infected infant born before the case and the next
HIV-exposed, uninfected infant born after the case at the
same hospital—were selected to control for evolving
PMTCT interventions provided over the study period.
HIV-exposed children who were diagnosed as HIV-infected
or uninfected after 18 months of age were excluded from
the study, as their medical records do not regularly contain
any information on the mothers’ sociodemographic data
nor antenatal and postnatal care. Second-born twins were
also excluded, as they have the same exposures but reduced
risk of MTCT compared to first borns [13]. Additionally,
mothers who were HIV-test negative during delivery were
excluded, as MTCT risk factors evaluated during the ante-
natal period would not apply.
Measures and data collection
Data were collected from mother and child medical re-
cords on a standardized intake form, based on the 2014
Protocol for Investigation of Vertical Transmission from
the BMoH [10]. The intake form included sociodemo-
graphic data of the mother as well as standard information
on antenatal care, birth, and postnatal care. All sociode-
mographic data reflect participant-reported information
except for participant’s race, which in Brazilian medical re-
cords is defined by the attending medical professional.
Data analysis
All data were analysed by Stata IC14 (Statacorp, College
Station, USA). We compared characteristics of matched
cases (HIV-infected infants and their mothers) and controls
(HIV-uninfected infants and their mothers) with condi-
tional logistic regression, which fits models for 1:x matched
case-control data (1:2 in the present study). Indicator vari-
ables were created from categorical variables for regression
analyses, and reference categories are indicated as 1 in
analysis tables. To evaluate residence in informal settle-
ments, we geocoded participant addresses with Google
Lovero et al. BMC Public Health  (2018) 18:1110 Page 2 of 10
Geocoding API v.3 (https://developers.google.com/maps/
documentation/geocoding/start). Participants whose ad-
dresses were incomplete (n = 60), could not be geocoded
(n = 18), or were homeless (n = 2) were excluded from
analysis. Remaining addresses were mapped to census
tracts (http://www.censo2010.ibge.gov.br) for federally
recognized informal settlements known as “aglomerados
subnormais” (AGSN) [14] with ArcGIS 10.4.1 (ESRI,
Redlands, CA, USA).
Results
Study population
Between 1997 and 2014, 266 MTCT cases were docu-
mented at the three research sites. Of these, 121 were ex-
cluded for the following reasons: 35 (28.9%) medical
records not located, 2 (1.7%) second twins, 8 (6.6%)
HIV-uninfected mothers at delivery, and 76 (62.8%) infants
diagnosed after 18 months of age. For the 145 cases in-
cluded in our study, two time-matched controls were
chosen at the cases’ respective hospitals (IFF: n = 55 (37.9%)
cases, n = 110 (37.9%) controls; HFSE: n = 38 (26.2%)
cases, n = 76 (26.2%) controls; HGNI: n = 52 (35.9%)
cases, n = 104 (35.9%) controls). Analysis of cases over the
study period showed that after an initial decline, an in-
crease in cases were reported between 2005 and 2008, but
decreased again so that by 2014 only one case was identi-
fied at our study sites (Fig. 1).
Sociodemographic characteristics
The median age at delivery was 26 years (IQR: 22 to 32)
for case and 27 (IQR: 22 to 31) years for control mothers.
Between time of HIV diagnosis and the pregnancy under
evaluation, case mothers were more likely than control
mothers to have not given birth to another child (OR:
1.97; 95% CI 0.99 to 3.90). No significant differences were
observed in race, marital status, education level, employ-
ment, drug use, and AGSN residence (Table 1).
PMTCT measures in cases and controls
In bivariate analysis of PMTCT measures, we found case
mothers and infants were more likely to have not com-
pleted each preventative step during antenatal care, de-
livery, and postnatal care (Table 2). Case mothers were
more likely to have had no antenatal care (OR: 3.10, 95%
CI: 1.68 to 5.70), and were more likely to not have been
diagnosed as HIV-infected until delivery (OR: 3.68, 95%
CI: 1.90 to 7.14) or after the birth of their child (OR:
11.21, 95% CI: 5.27 to 23.36. Of women who completed
at least one antenatal visit, there was no significant dif-
ference in gestational age at which case and control
mothers entered antenatal care. However, case mothers
were more likely to not antenatal care at an HIV refer-
ence centre (OR: 19.78, 95% CI: 5.65 to 69.24), where it
is protocol that all HIV-infected mothers be referred
after a positive diagnosis [15]. Additionally, case mothers
were more likely to not initiate or complete antenatal
ART (aART) (OR: 19.41, 95% CI: 8.72 to 43.21). Evaluat-
ing only mothers who completed aART, there was no
significant difference in ART regimen. During delivery,
case mothers were more likely to not be administered
intravenous AZT (OR: 4.89, 95% CI: 2.91 to 8.24) and to
not deliver by Caesarean section (OR: 1.73, 95% CI: 1.11
to 2.71). No significant difference was found in the ges-
tational age at birth, nor in membrane rupture times less
than 4 h long (data not shown). In the postnatal period,
case infants were more likely to not use oral ARVs
Fig. 1 Number of cases included at study sites for each year of study period
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(OR: 12.10, 95% CI: 5.79 to 25.27) and to be breastfed
(OR: 5.44, 95% CI: 2.84 to 10.40).
Completion of PMTCT cascade
While the analysis in Table 2 provides an overall assess-
ment of the completion of each PMTCT measure, be-
cause these measures are dependent upon one another,
it may be that the differences seen between cases and
controls throughout the PMTCT cascade are driven by
incompletion of earlier steps by cases. For example, a
woman who was not diagnosed as HIV-infected before
or during delivery would not have been eligible to re-
ceive aART or intravenous AZT in delivery. To deter-
mine if differences in PMTCT completion between cases
and controls persisted independent of prior gaps in care,
we next analysed completion of the PMTCT cascade
only among participants eligible for each step (Fig. 2).
Of women who attended at least one antenatal visit
(n = 213 controls, n = 60 cases), just 25 case (41.7%) com-
pared to 169 control (79.3%) mothers were diagnosed as
HIV-infected (OR: 0.25, 95% CI: 0.10 to 0.65). Of these
women who were known to be HIV-infected in the
Table 1 Sociodemographic characteristics of case and control mothers
Controls (n = 290) N (%) Cases (n = 145) N (%) OR (95% CI) pa
Median Age, Years (Interquartile Range) 26 (22–32)b 27 (22–31)c 1.01 (0.97–1.05) 0.64
Race
White 94 (32.4) 28 (19.3) 1
Mixed Race 97 (33.5) 40 (27.6) 1.72 (0.90–3.29) 0.10
Black 53 (18.3) 30 (20.7) 1.30 (0.73–2.32) 0.37
No information 46 (15.9) 47 (32.4) 4.21 (2.17–8.13) < 0.000
Marital Status
Single 67 (23.1) 40 (27.6) 1
Married 119 (41.0) 55 (37.9) 0.77 (0.47–1.29) 0.32
No information 104 (35.9) 50 (34.5) 0.80 (0.46–1.39) 0.43
Education Level
None 7 (2.4) 3 (2.1) 1
Some or all primary school 167 (57.6) 72 (49.7) 1.42 (0.22–9.36) 0.71
Some or all secondary school 61 (21.0) 18 (12.4) 1.07 (0.15–7.60) 0.94
Some or all college 5 (1.7) 1 (0.7) 0.89 (0.05–16.10) 0.94
No information 50 (17.2) 51 (35.2) 4.67 (0.65–33.60) 0.13
Employment
Unemployed/Home Maker 126 (43.5) 52 (35.9) 1
Employed 69 (23.8) 21 (14.5) 0.80 (0.43–1.47) 0.47
Student 8 (2.8) 2 (1.4) 0.58 (0.12–2.81) 0.50
No information 87 (30.0) 70 (48.3) 2.29 (1.36–3.83) 0.002
Drug Use
Yes 44 (15.2) 22 (15.2) 1
No 102 (35.2) 38 (26.2) 0.77 (0.41–1.46) 0.43
No information 144 (49.7) 85 (58.6) 1.48 (0.75–2.95) 0.26
Residence
AGSN 49 (16.9) 14 (9.7) 1
Non-AGSN 207 (71.4) 87 (60.0) 1.49 (0.78–2.85) 0.23
No information 34 (11.7) 44 (30.3) 5.68 (2.50–12.88) < 0.000
Other Child Since Diagnosis
Yes 53 (18.3) 14 (9.7) 1
No 164 (56.6) 83 (57.2) 1.97 (0.99–3.90) 0.05
No information 73 (25.2) 48 (33.1) 2.74 (1.3105.71) 0.007
aConditional logistic regression; bn = 252; cn = 105
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antenatal period, only 12 (48%) case compared to 154
(91.1%) control mothers completed aART (OR: 0.08,
95% CI: 0.03 to 0.24). However, when we evaluated only
women known to be HIV-infected who attended any ante-
natal care at a PMTCT reference centre, per Brazilian
protocol for HIV-infected expectant mothers, there was no
significant differences in the portion of case (n = 11, 100%)
compared to control (n = 148, 97.3%) mothers who com-
pleted aART. Additionally, considering only mothers who
had been diagnosed but had no or unknown antenatal care,
only 3 cases (15%) compared to 12 controls (50%) com-
pleted aART (OR: 0.18, 95% CI: 0.03 to 0.88).
Evaluating completion of the PMTCT cascade during
delivery, we first assessed all mothers who had been
Table 2 PMTCT measures in case and control mothers
Controls (n = 290) N (%) Cases (n = 145) N (%) OR (95% CI) pa
Antenatal Care
Yes 213 (73.5) 60 (41.2) 1
No 32 (11.0) 29 (20.0) 3.10 (1.68–5.70) < 0.000
No information 45 (15.5) 68 (38.6) 5.62 (3.11–10.13) < 0.000
Time of Diagnosis
Before/during antenatal 192 (66.2) 41 (28.3) 1
During delivery 56 (19.3) 36 (24.8) 3.68 (1.90–7.14) < 0.000
After birth 14 (4.8) 36 (24.8) 11.21 (5.27–23.36) < 0.000
No information 28 (9.7) 32 (22.1) 6.01 (2.96–12.19) < 0.000
Gestational Age at First Visit 18.8 (0.9)b 22.3 (2.4)c 1.07 (0.99–1.15) 0.11
Antenatal Location
Some or all in reference centre 157 (60.9) 14 (12.1) 1
No reference centre 56 (21.7) 46 (39.7) 19.78 (5.65–69.24) < 0.000
No information 45 (17.4) 56 (48.3) 37.47 (10.73–130.84) < 0.000
Antenatal ART
Yes 169 (58.3) 16 (11.0) 1
No 95 (32.8) 101 (69.7) 19.41 (8.72–43.21) < 0.000
No information 26 (9.0) 28 (19.3) 14.91 (5.71–38.93) < 0.000
Antenatal ART Regimen
Triple ARV 71 (42.0) 8 (50.0) 1
AZT only 98 (58.0) 8 (50.0) 1.38 (0.43–4.43) 0.54
Intravenous AZT during Delivery
Yes 190 (65.5) 41 (28.3) 1
No 55 (19.0) 62 (42.8) 4.89 (2.91–8.24) < 0.000
No information 45 (15.5) 42 (29.0) 4.31 (2.38–7.80) < 0.000
Type of Birth
Caesarean 174(60.0) 59 (40.7) 1
Vaginal 94 (32.4) 57 (39.3) 1.73 (1.11–2.71) 0.02
No information 22 (7.6) 29 (20.0) 3.74 (1.98–7.09) < 0.000
ART in Infant
Yes 250 (86.2) 65 (44.8) 1
No 12 (4.1) 42 (29.0) 12.10 (5.79–25.27) < 0.000
No information 28 (9.7) 38 (26.2) 8.60 (4.04–18.26) < 0.000
Formula Only
Yes 243 (83.8) 74 (51.0) 1
No 15 (5.2) 31 (21.4) 5.44 (2.84–10.40) < 0.000
No information 32 (11.0) 40 (27.6) 4.87 (2.60–9.15) < 0.000
aConditional logistic regression; bn = 101; cn = 19
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diagnosed before or during the antenatal period, regard-
less of whether their records showed evidence of any
antenatal care (n = 192 controls, n = 41 cases), as this is
not necessary for completion of cascade steps we evalu-
ated during delivery. Of these mothers, just 24 (58.5%)
cases compared to 149 (77.6%) controls received intra-
venous AZT during delivery (OR: 0.17, 95% CI: 0.03 to
0.80). However, of mothers diagnosed as HIV-infected
during delivery (n = 56 controls, n = 36 cases), only 12
(33.3%) cases and 30 (53.6%) control mothers received
intravenous AZT (OR: 0.27, 95% CI: 0.06 to 1.27).
Assessing interventions in the postnatal period, 248
control and 77 case infants were born to women who
had been diagnosed before or during delivery. Of these
infants, only 53 (68.8%) cases compared to 225 (90.7%)
controls were treated with oral ARVs (OR: 0.14, 95% CI:
0.03 to 0.67). Moreover, just 57 (74%) case compared to
221 (89.1%) control infants were fed a formula-only diet
(OR: 0.28, 95% CI: 0.09 to 0.83).
Progress towards the elimination of MTCT
In its 2017 guide to elimination of MTCT (EMTCT),
the WHO laid out indicators on the path to EMTCT, in-
cluding 1) at least one antenatal visit, 2) coverage of
HIV testing for pregnant women, and 3) aART coverage
in HIV-infected pregnant women [16]. To determine
progress toward these goals, we assessed antenatal care
attendance, antenatal diagnosis, and aART completion in
all mothers across the study period (Fig. 3). Engagement
in antenatal care improved over the years, though only
83.3% (n = 5) of mothers were known to have attended
at least one visit in 2014 (Fig. 3a). HIV diagnosis before
or during the antenatal period decreased between 2005
and 2010, but increased again in the final years of the
study period, such that 83.3% (n = 5) of mothers were di-
agnosed in 2014. To evaluate completion of the PMTCT
cascade, we also assessed HIV diagnosis only in women
who attended any antenatal care, and found it increased
only slightly over time, with just 80% (n = 4) of mothers
diagnosed in 2014 (Fig. 3b). Completion of aART in-
creased over the study period, although only 66.7% (n = 4)
of women were shown to have completed aART in 2014.
Again, evaluating only mothers engaged in the PMTCT
cascade (those who attended any antenatal care and were
diagnosed as HIV-infected), we found that aART comple-
tion among these women remained fairly high throughout
the study period, although still just 80% (n = 4) of mothers
completed aART in 2014 (Fig. 3c).
Motives for not completing PMTCT steps
Our analysis of completion of the PMTCT cascade
(Figs. 2 and 3) demonstrated that a large portion of
mothers who entered antenatal care did not complete all
antenatal steps. To better understand the contribution of
lack of care-seeking, care abandonment, and failure to
provide services to gaps in PMTCT coverage, we assessed
the motives for which mothers were not diagnosed in the
antenatal period and did not initiate or complete aART.
Motives were classified based on the BMoH protocol for
investigation into vertical transmission of HIV [10]. Of the
70 control mothers who were not diagnosed before or
during the antenatal period, 18 (25.7%) did not attend any
Completed prevention step
Did not complete prevention step
No information
Successful completion of cascade step
213 60
169 (79.3%) 25 (41.7%) 2 (3.3%)33 (55.0%)
12 (7.1%)154 (91.1%) 1 (4.0%)12 (48.0%)
8 (3.2%)221 (89.1%) 57 (74.0%)
5 (2.0%)225 (90.7%) 9 (11.7%)53 (68.8%) 
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Fig. 2 Completion of PMTCT cascade. Number and percentage, in parentheses, of study participants who completed, did not complete, or lacked
information on each preventative measure they were known to be eligible to receive. Arrows indicate steps in completion of the PMTCT cascade.
Lovero et al. BMC Public Health  (2018) 18:1110 Page 6 of 10
antenatal care, 3 (4.3%) did not have an HIV test ordered,
6 (8.6%) did not receive test results, 1 (1.4%) did not have
HIV testing available at the clinic, 2 (2.9%) abandoned
antenatal care, and 40 (57.1%) had unknown motives. Of
the 72 case mothers not diagnosed before or during the
antenatal period, 14 (19.4%) did not attend any antenatal
care, 3 (4.2%) did not have an HIV test ordered, 13
(18.1%) did not receive test results, 2 (2.8%) did not have
HIV testing available at the clinic, and 40 (55.6%) had un-
known motives. We next evaluated motives for incom-
plete aART in mothers who had been diagnosed before or
during the antenatal period. Of the 25 control mothers
who were diagnosed as HIV infected and did not complete
aART, 13 (52%) did not attend any antenatal care, 3 (12%)
were not offered aART, 1 (4%) refused/abandoned treat-
ment, 2 (8%) initiated antenatal care too late in pregnancy
to begin ART, and no information on motive was available
for 6 (24%). Of the 29 case mothers who were diagnosed
but did not complete aART, 11 (37.9%) did not attend any
antenatal care, 1 (3.4%) was not offered aART, 3 (10.3%)
refused/abandoned treatment, 2 (6.9%) initiated antenatal
care too late in pregnancy to begin ART, and no informa-
tion on motive was available for 12 (41.4%).
Coinfections associated with MTCT
In comparing frequencies of other congenital infections,
we found that 21 (14.5%) case but only 10 (3.5%) control
infants were diagnosed to have syphilis (OR: 4.29; 95% CI:
1.66 to 11.11). There was no significant difference in
Hepatitis C, Hepatitis B, CMV, or toxoplasmosis infection
of case and controls infants.
Discussion
Despite innovative and aggressive public health efforts
made in the prevention and treatment of HIV infection
[17], Brazil has still not achieved its stated goal for 2015
of eliminating MTCT [10]. Here, we found that cases of
MTCT were significantly less likely to complete all
PMTCT measures in the antenatal, perinatal, and postnatal
periods. Evaluating the PMTCTcascade, we identified inad-
equate retention in care throughout the cascade for both
cases and controls, although cases were significantly less
likely than controls to continue receiving care throughout
the cascade. Importantly, temporal analysis of antenatal
PMTCT steps showed that, although PMTCT completion
has increased modestly over the study period, the study
sites are still not meeting the 95% coverage goal for ante-
natal care, HIV testing, and aART set by the WHO.
Research across various regions of Brazil has shown
that lack of antenatal care and late diagnosis underlie
substantial gaps in the PMTCT cascade [8, 12, 18–20].
In our cohort, while 19% of case and 29% of control
mothers were not diagnosed prior to birth because they
had not attended any or abandoned antenatal care, 25%
of case and 14% of control mothers did not receive their
diagnosis due to a failure in antenatal services—tests not
being available, not ordered, or results not reported. More-
over, 55% of case and 64% of controls mothers who were
diagnosed as HIV-infected did not complete aART because
of failure to seek antenatal care or refusal/abandonment of
treatment, although 12% of controls and 3% of cases were
not offered aART. Infrastructural issues—including long
delays in scheduling antenatal visits [21, 22], lack of HIV
testing services delays in reporting results [22, 23], and
insufficient training of healthcare workers [21, 23]—all
have been shown to contribute to decreased PMTCT
initiation and completion in Brazil. Therefore, in addition
to promoting care-seeking behaviour among Brazilian
mothers, it is also important to address issues in availability
of antenatal services and training of workers.
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In addition to missed opportunities owing to lack of
antenatal care and late HIV diagnosis, we identified gaps
in treatment for women who were aware of their HIV
status throughout the PMTCT care cascade. In the ante-
natal period, only 86% of the mothers who attended
antenatal care and received their HIV diagnosis com-
pleted aART. Previous research in other regions of Brazil
has shown similar percentages of pregnant women not
completing aART. In the northern state of Amazonas,
aART completion increased only 10% between 1999 and
2011, with 20% of women not completing ART in 2011
[8]. A similar situation was shown in the southern state
of Rio Grande do Sul, where aART use grew 13% be-
tween 1998 and 2011, but over 25% of women still did
not complete aART between 2005 and 2011 [24]. More-
over, a study conducted in the southern state of Paraná
found that 16% of women did not complete aART be-
tween 2007 and 2012 [25]. However, UNAIDS reported
over 95% of all pregnant women to be receiving aART in
Brazil in 2015 [26]. It is possible that the aART gap
closed significantly in one year, or that these and our
studies are not representative of Brazil as a whole, but
more likely that this difference reflects a disparity in the
number of women receiving versus completing aART in
Brazil. Supporting this hypothesis, 10% of the case and
4% of controls mothers in our study were prescribed
aART but abandoned treatment. Notably, 100% of case
and 97% of control mothers who attended antenatal care
at a reference centre completed aART, indicating that a
focus on improving the connection between general and
PMTCT reference antenatal services may help close the
gap in aART completion.
Other significant missed opportunities for PMTCT
were observed in delivery and postnatal care of our
study cohort. Caesarean section is recommended in
women with unknown or viral loads above 1000 copies/
mL [15]. Because the medical records lacked data on
maternal viral load, we could not precisely define the
percentage of women who did not undergo Caesarean
section in cases where protocol would have called for it.
However, knowing that 70% of case mothers did not
complete aART, and only 41% delivered by Caesarean
section, it is clear that a large portion of case mothers in
our study, whose HIV infection was not managed in the
antenatal period, did not undergo Caesarean section.
Additionally, only 66% of mothers who were diagnosed
before or during delivery received intravenous AZT dur-
ing delivery, and just 86% of infants born to mothers
who had been diagnosed as HIV-infected used oral
ARVs and were exclusively formula fed, supporting the
need for increased efforts to promote completion of the
PMTCT cascade beyond antenatal care.
Another important finding in our study is that the fre-
quency of syphilis was significantly higher in case infants.
In Brazil, reports of congenital syphilis grew by over 300%
between 2005 and 2015, and 44% of syphilis-infected preg-
nant women were not diagnosed until after delivery [27].
Dual elimination of mother-to-child transmission of HIV
and syphilis was recently recognized by the WHO as a
global health priority [28]. Occurrence of syphilis in the
case women in our study most likely reflects absence of
antenatal screening, and efforts to improve uptake and re-
tention in antenatal HIV services can also support reduc-
tion in MTCT of syphilis.
Although there are still gaps in preventative treatment,
the population not receiving care in Brazil is small. How-
ever, especially considering rising HIV rates in Brazil over
the last decade [29], to achieve EMTCT this population
must be identified and targeted. Our analysis of sociode-
mographic factors did not reveal any significant differ-
ences between cases and controls. Owing to our use of
retrospective data collection, this may be due to high pro-
portions of missing sociodemographic data. Previous re-
search has shown that psychosocial factors—including
stigma, lack of social support, and distrust or misunder-
standing of antenatal care [21]--contribute to decreased
PMTCT initiation and completion in Brazil. Thus, pro-
spective studies on sociodemographic indicators of MTCT
risk as well as efforts to address psychosocial barriers must
be carried out together to achieve elimination goals.
Due to the retrospective nature of this study, we were
limited to collecting data commonly found in medical
records and thus were not able to evaluate maternal viral
load and other socioeconomic indicators. Additionally,
we were unable to obtain complete data from medical
charts of many of the study participants, due to missing
information. Interestingly, cases were more likely to have
missing information, which suggests that they were less en-
gaged in care throughout the PMTCT cascade. While our
use of matched controls allowed us to control for changes
in provision of services (e.g. government-provided formula
in 2002) and improvements in PMTCT regimens (e.g. triple
ARV introduction in 2007) when assessing risk factors for
MTCT, it limited our analysis in that we were not able to
evaluate potential differences between PMTCT sites.
Conclusions
Although PMTCT coverage improved over the course of
the study period, to succeed in eliminating MTCT of HIV
in Brazil, it is critical that efforts be made to increase uptake
and retention in PMTCT services to promote early diagno-
sis and completion of all steps in the PMTCT cascade. Spe-
cifically, identification of socioeconomic and psychosocial
barriers to accessing care as well as improvements in
PMTCT infrastructure are required. The impact of im-
provements in antenatal care has significance beyond re-
ductions in HIV transmission, as increased engagement in
Lovero et al. BMC Public Health  (2018) 18:1110 Page 8 of 10
antenatal care is also critical to addressing rising national
rates of congenital syphilis.
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